Search Results
Your search for early matches 10332 pages
Showing 1451 - 1500Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel when compared to the current standard-of-care chemoimmunotherapy, according to results of the...
Narjust Florez, MD, and Heather A. Wakelee, MD, on Early-Stage NSCLC: Phase III Findings From KEYNOTE-671 on Pembrolizumab and Platinum-Based Chemotherapy
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Heather A. Wakelee, MD, of Stanford University, Stanford Cancer Institute, discuss new data supporting neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab as a promising new treatment option for patients ...
Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit...
Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative...
Ciltacabtagene Autoleucel Reduces Risk of Disease Progression in Patients With Lenalidomide-Refractory Multiple Myeloma
Ciltacabtagene autoleucel, a B-cell maturation antigen–targeting chimeric antigen receptor (CAR) T-cell therapy, significantly slows or stops progression of multiple myeloma when compared with standard-of-care treatments among patients with lenalidomide-refractory disease. Results from the...
Chemotherapy-Induced Peripheral Neuropathy May Be More Severe With Paclitaxel Than With Docetaxel
Researchers have found that patients who have breast cancer who undergo treatment with taxanes show a pattern of clinically meaningful, persistent sensory and motor symptoms associated with chemotherapy-induced peripheral neuropathy, according to new findings presented by Trivedi et al at the 2023...
Jennifer A. Ligibel, MD, on Early Breast Cancer and Weight Loss: Results From the BWEL Trial
Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute, discusses a telephone-based weight loss intervention that induced clinically meaningful weight loss in patients with breast cancer who had overweight and obesity, across demographic and tumor factors. Additional tailoring of the intervention ...
Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options
Manali K. Kamdar, MD, of University of Colorado Hospital, discusses the treatment landscape for the 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) whose disease will relapse. Patients who experience relapse within 1 year of chemoimmunotherapy have poor outcomes with...
Radiation May Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer
Patients with locally advanced rectal cancer with tumors that respond to chemotherapy may safely forgo radiation therapy before surgery, based on the findings of the PROSPECT trial. These data were presented by Deborah Schrag, MD, FASCO, MPH, at the 2023 ASCO Annual Meeting (Abstract LBA2) and...
Patients With SLFN11-Expressing SCLC May Benefit From Immune Checkpoint Inhibitor Plus PARP Inhibitor
Among patients with extensive-stage small cell lung cancer (SCLC) positive for expression of the Schlafen-11 gene (SLFN11), those who received maintenance treatment with the immune checkpoint inhibitor atezolizumab plus the PARP inhibitor talazoparib had significantly longer progression-free...
Changes in RECIST Tumor Measures Correlate Linearly With Survival in Patients Treated With Checkpoint Inhibitors
The Response Evaluation Criteria in Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories—complete response, partial response, stable disease, or progressive disease—based on the percent of...
Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell...
Early Cessation of Neoadjuvant Chemotherapy May Lead to Worse Outcomes in Patients With Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer who receive fewer than three cycles of chemotherapy prior to cystectomy may have an increased risk of cancer recurrence and worse survival outcomes, according to the findings of a retrospective study presented by Chakraborty et al at the 2023 ASCO Annual ...
Addition of Olaparib and Durvalumab to Standard of Care May Prolong Progression-Free Survival in Patients With Advanced Ovarian Cancer
Patients with newly diagnosed advanced ovarian cancer without a BRCA mutation who received durvalumab and olaparib in addition to the standard of care had improved progression-free survival compared with those who received the standard of care alone, according to the interim analysis of DUO-O, an...
Adding Ribociclib to Endocrine Therapy May Reduce Recurrence Risk in Patients With Hormone Receptor–Positive, HER2-Negative Early-Stage Breast Cancer
Adding the CDK4/6 inhibitor ribociclib to endocrine therapy resulted in a significant improvement in invasive disease–free survival for patients with hormone receptor–positive, HER2-negative early-stage breast cancer. Findings from the phase III NATALEE trial were presented by Dennis J. Slamon, MD, ...
Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer
Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from the large, international phase III SHAPE clinical trial. The research was presented by Plante...
Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection
Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. The...
Study Finds Wide Variations in Intratumoral Microbiome of Patients With Early- vs Late-Onset Colorectal Cancer
Researchers have found that the bacteria, fungi, and viruses within the tumors of patients with colorectal cancer varied significantly depending on whether they were diagnosed with early-onset or late-onset disease, according to new findings presented by Weinberg et al at the 2023 ASCO Annual...
Finding Early Female Role Models Helped Shape a Notable Career in Oncology
Elizabeth M. Jaffee, MD, Deputy Director of The Sidney Kimmel Comprehensive Cancer Center, Baltimore, was born in Brooklyn, New York, in a place and time she found exhilarating during her early years. “We didn’t have a lot of money—actually, we were poor. But I had a lot of freedom walking around...
Daughter of Immigrants Who Fled the Pogroms, She Followed a Love of Science Into a Noted Career in Cancer Pathology
In the era of genomics and precision medicine, the role of pathology in diagnosis and cancer management is rapidly evolving. For the past 50 years, from her office at the Center for Cancer Research, National Cancer Institute (NCI), pathologist Elaine S. Jaffe, MD, has been at the forefront of that...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
Involvement in SWOG and JCO Leads to a Fulfilling Career as a Leader in Oncology
Jonathan W. Friedberg, MD, MMSc, Director of the James P. Wilmot Cancer Institute, grew up in a suburb of Milwaukee. While his school friends were attending camp, he spent his summers working on the family farm. “Perhaps the hardest work I’ve ever done was haying on a hot, humid night in July,...
The Second-Generation Son of Greek Immigrants, the First to Go to College, Becomes a Leader in Sarcoma Research and Treatment
George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Professor of Medicine and Co-Director of the Ludwig Center at Harvard, was born in Hyde Park, a town along the Hudson River in New York. When Dr. Demetri was growing up there, it was known for three...
HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes
Early-phase data from the SOLTI TOT-HER3 and ICARUS-BREAST01 trials suggest that the novel HER3-directed antibody-drug conjugate patritumab deruxtecan may have beneficial activity in patients with hormone receptor–positive/HER2-negative and triple-negative breast cancer subtypes, according to...
Mourned and Missed
The respected members of the oncology community listed here are among some of those who passed away in 2022–2023. The ASCO Post remembers them, their lives, and their contributions to cancer research and treatment. Robert J. Gillies, PhD Moffitt Cancer Center and the global research community lost ...
A Leader in Oncology From Humble Beginnings Never Forgets Life Lessons Learned Along the Way
In December 2019, Robert A. Winn, MD, became the second Black physician to lead a National Cancer Institute (NCI)-designated comprehensive cancer center when he took the helm of the Virginia Commonwealth University (VCU) Massey Cancer Center. Dr. Winn’s basic science research, which has been...
A Love of Immunology Leads to a Notable Career in Dermatology, With a Focus on Melanoma Research and Treatment
Caroline Robert, MD, PhD, Head of the Dermatology Unit at Gustave Roussy and Co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, was born and reared in Paris. “I didn’t have a vocation for medicine when I was a kid; I wanted to be an archeologist. I’m not from a medical...
Inspired by an Uncle Who Was a Compassionate Family Doctor, This Nonagenarian Continues a Renowned Career in Hematology
Today is the era of the multidisciplinary oncology care approach, cancer staging facilitates precision in documenting disease extent, all of which improved the quality of patient care. However, in the United States, the Rai staging system is still the most commonly used clinical staging system for...
From a Small Town in North Carolina, a Young Girl Finds Her Calling in Battling Inequity in Cancer Care
Manali Patel, MD, MPH, Associate Professor of Medicine (Oncology) at Stanford University, grew up in Shelby, a small town in the textile and farming community of Western North Carolina, among mill workers and other blue-collar laborers. The daughter of Indian immigrants, Dr. Patel’s early life was...
A Free-Spirited Childhood on a Dairy Farm, Where Books and Science Experiments Were Encouraged
Susan K. Parsons, MD, MRP, Professor of Medicine and Pediatrics at Tufts University School of Medicine and Founding Director of the Reid R. Sacco Adolescent and Young Adult Program for Cancer and Hereditary Blood Disorders at Tufts Medical Center, grew up on a working dairy farm in Sharon Springs,...
FDA Approves Flotufolastat Fluorine-18 Injection, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer
On May 30, the U.S. Food and Drug Administration (FDA) approved the optimized, high-affinity radiohybrid prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging agent flotufolastat fluorine-18 (Posluma). Flotufolastat F-18 is indicated for PET imaging of...
Incidence of Colorectal, Lung, and Breast Cancers May Be Rising Due to COVID-19–Related Screening Delays
Delays in cancer screenings during the COVID-19 pandemic may have resulted in lower reported incidences of colorectal, lung, and breast cancers, reflecting potentially high rates of undiagnosed cancer and later-stage diagnoses, according to a new study published by Romatoski et al in the Journal of ...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award...
Disparities in Cancer Care: A Bangladeshi Perspective
The fight against cancer has made remarkable progress worldwide over the past decade. Through corporate investment in research and technology, the incidence of cancer and death rates in developed nations have steadily declined. The number of people living longer and fuller lives after a cancer...
Northwell Launches Cancer Care Direct, Pairing Nurse Navigators With Patients Through Spectrum of Care
Knowing the health-care system is complex and often creates anxiety for patients newly diagnosed with cancer, the Northwell Health Cancer Institute has launched Cancer Care Direct, a comprehensive program to connect patients with clinical registered nurse navigators who can provide expert guidance...
Surviving, but Not Always Thriving, After Cancer
As discussed in Part I of this special feature on cancer survivorship, there are now more than 18 million cancer survivors in the United States, and that number is expected to grow to 26 million by 2040.1 However, most of those survivors—at least two-thirds—either cured or in remission or living...
Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification
In an analysis recently reported in the Journal of Clinical Oncology,1 Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to intermediate risk from high risk based on a change in the minimum age...
Surviving, but Not Always Thriving, After Cancer
The improvement in cancer survival rates since President Richard M. Nixon signed the National Cancer Act of 1971 into law is staggering. The legislation further committed the United States to greater investments in cancer-focused research to drive down the rates of cancer diagnoses, boost patient...
American College of Surgeons Evaluates the Impact of COVID-19 Pandemic on National Cancer Database Reporting
New research from the American College of Surgeons (ACS) outlines significant ways that the COVID-19 pandemic destabilized usual patterns of cancer care, as reported in the National Cancer Database (NCDB). The NCDB is one of the largest cancer registries in the world and is used by thousands of...
Radiation Oncology Workforce Expected to Remain Stable Through 2030
A new analysis of the U.S. radiation oncology workforce projects a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030.1 The report was produced by Health Management Associates (HMA), a consulting firm commissioned by the American...
Playing a Doctor in a School Play Sparked an Early Desire to Become a Real Doctor for Sibylle Loibl, MD, PhD
For this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sibylle Loibl, MD, PhD, Chair of the German Breast Group (GBG) and Chief Executive Officer of the GBG Forschungs GmbH. Professor Loibl, Associate Professor of Obstetrics and Gynecology ...
Prevalence of Functional Limitations in U.S. Cancer Survivors
In a study reported in a research letter in JAMA Oncology, Patel et al found that the prevalence of self-reported functional limitations in U.S. cancer survivors increased between 1999 and 2018. Study Details The analysis included adults in the 1999 to 2018 National Health Interview Survey (NHIS)...
Genetic Sequencing May Identify Cancers Often Missed by Traditional Screening Guidelines
Whole-exome sequencing of a large database identified carriers of mutations associated with hereditary cancer syndromes (ie, hereditary breast and ovarian cancers and Lynch syndrome). What was surprising was that among those carriers, about 40% did not satisfy the existing National Comprehensive...
Expert Point of View: Stephen Lam Chan, MD
Invited discussant of the IMbrave050 trial, Stephen Lam Chan, MD, of Chinese University of Hong Kong, put the study into context. “After curative treatment, recurrence remains a big problem [in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or...
IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
Israeli Surgical Oncology Leader Dov Zippel, MD, Considers the Evolving Landscape of Cancer Care in a Small Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Dov Zippel, MD, a surgical oncologist at Sheba Medical Center in Tel Hashomer, Israel, where he is Head of the Meirav Breast Center. Dr. Zippel is the current President of ...
Novel Bispecific Antibody for Multiple Myeloma Shows High Response Rates in Early Trial
The bispecific antibody REGN5459 achieved a 90.5% overall response rate when given at the two highest doses in patients with relapsed or refractory multiple myeloma, according to the results of a phase I/II clinical trial.1 Although preliminary, the results of this first-in-human trial for the...
Assay Prediction of pCR in Patients With HER2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
In an analysis reported in JAMA Oncology, Waks et al found that the HER2DX assay performed well in predicting the likelihood of pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving de-escalated neoadjuvant treatment with paclitaxel, trastuzumab, and...
Late Major Surgical Intervention in Survivors of Childhood Cancer
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in The Lancet Oncology, Dieffenbach et al found that childhood cancer survivors had a heavy cumulative burden of late major surgical interventions. Study Details The study involved data from the CCSS on 5-year survivors of...
Exercise, Wellness Interventions in Early Breast Cancer Demonstrate Measurable Benefits—Even Economic Ones
Specialized exercise and wellness programs significantly elevated physical well-being and quality of life among patients with breast cancer while reducing the use of health-care resources in new research presented at the 2023 American Society of Breast Surgeons Annual Meeting. In one multicenter...
